Skip to main content
OpenTrials
Completed

NCT Number: NCT05111392

Hydration Dynamics and Influence of Beverage Composition

The study examines interactions between fluid availability in the gut and fluid retention in the body. The relative rate of fluid uptake, the expansion of the plasma volume, and percent of fluid retained by the body will be measured in response to ingestion of beverages of different composition. Healthy, euhydrated adults will be studied. The results will help establish formulations of beverages that sustain if not promote acute euhydration.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Illinois Chicago

Chicago, Illinois, 60612, United States

About this study

Using a randomized order for beverage treatments at three separate trials, subjects will ingest 1 Liter of one of three beverages in 10 minutes: water, a beverage with 2.5% glucose with 45 mmol sodium/L, or a beverage with 1.7% glucose with 60 mmol sodium/L. Before and repeatedly for 2 h after ingestion of the beverage, blood samples will be drawn for assessments of D2O, Hb, Hct, osmolality, sodium, and glucose. The rate of appearance of D2O will be evaluated using the area under the curve, the slope of the appearance, and half time to plateau. Comparisons will be made between beverages for indices of the rate of appearance of D2O, the change in PV over time, and cumulative urine excreted. The cumulative urine produced will be used to calculate a modified BHI for the two glucose-electrolyte beverages and water for comparison with 1.0 (expected for no beverage effect). We hypothesize faster absorption (D2O appearance rate), and better overall hydration (expanded PV and higher modified BHI) will occur for beverages containing glucose and sodium compared to water. Further, we hypothesize that of the electrolyte beverages, the beverage with higher sodium content will promote greater overall hydration (less urine excreted) than the beverage with lower sodium.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have a BMI of 18.5 to 29.9 kg/m2.
  • Be normotensive (<120/80 mm Hg).
  • Must be able to speak and read English.
  • Be physically active or a regular exerciser but be able to abstain from exercise for 48 h prior to each study trial.
  • Fast for at least 8 hours prior to and through the study trial.
  • Be able to abstain from alcohol for 48 h prior to each study.
  • Be able to abstain from caffeine for 24 h prior to each study.
  • If female, must have regular menstrual cycles, that are > 27 days and < 35 days in length.

Exclusion criteria

  • Under 18 y of age or over 45 y of age.
  • Have a BMI <18.5 or >30.
  • Being pregnant.
  • Lactating.
  • Tobacco user.
  • Have hypotension or hypertension.
  • Have any type of kidney disease or dysfunction.
  • Have diabetes.
  • Have any type of cardiovascular disease.
  • Have been diagnosed with galactosemia.
  • Females with irregular menstrual cycles.
  • Females with polycystic ovary disease.

Treatment and study plan

Placebo

Biological

Ingestion of one (1) liter of beverage with observation for 2 h

Oral Rehydration Solution 1

Biological

Ingestion of one (1) liter of beverage with observation for 2 h

Oral Rehydration Solution 2

Biological

Ingestion of one (1) liter of beverage with observation for 2 h

Primary outcomes

  1. Rate of appearance of deuterium in the plasma for placebo

    Time frame: 2 hours

    Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.

  2. Rate of appearance of deuterium in the plasma for oral rehydration solution 1.

    Time frame: 2 hours

    Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.

  3. Rate of appearance of deuterium in the plasma for oral rehydration solution 2.

    Time frame: 2 hours

    Measure the rate of fluid uptake by the gut using appearance of deuterium oxide, or D2O, in the blood after ingesting a fixed volume of placebo.

Secondary outcomes

  1. Fluid retention for placebo

    Time frame: 2 hours

    Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.

  2. Fluid retention for oral rehydration solution 1

    Time frame: 2 hours

    Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.

  3. Fluid retention for oral rehydration solution 2

    Time frame: 2 hours

    Measure fluid retention using the difference between ingested volume and cumulative urine excretion as a percentage of the ingested volume.

  4. Change in plasma volume for placebo

    Time frame: 2 hours

    Increase in plasma volume (water content of the blood) following ingestion of beverage

  5. Change in plasma volume for oral rehydration solution 1

    Time frame: 2 hours

    Increase in plasma volume (water content of the blood) following ingestion of beverage

  6. Change in plasma volume for oral rehydration solution 2

    Time frame: 2 hours

    Increase in plasma volume (water content of the blood) following ingestion of beverage

Sponsors and collaborators

Lead sponsor

University of Illinois at Chicago

Other

Registry information

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Nov 8, 2021
Registry last updated
Jul 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.